KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Esperion Therapeutics (ESPR) EBIT: 2018-2025

Historic EBIT for Esperion Therapeutics (ESPR) over the last 7 years, with Sep 2025 value amounting to -$10.0 million.

  • Esperion Therapeutics' EBIT rose 37.86% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$29.4 million, marking a year-over-year decrease of 278.55%. This contributed to the annual value of $54.4 million for FY2024, which is 134.97% up from last year.
  • Latest data reveals that Esperion Therapeutics reported EBIT of -$10.0 million as of Q3 2025, which was down 240.37% from $7.1 million recorded in Q2 2025.
  • Esperion Therapeutics' 5-year EBIT high stood at $72.3 million for Q1 2024, and its period low was -$82.8 million during Q1 2021.
  • For the 3-year period, Esperion Therapeutics' EBIT averaged around -$11.5 million, with its median value being -$16.0 million (2024).
  • Its EBIT has fluctuated over the past 5 years, first spiked by 248.69% in 2024, then slumped by 130.57% in 2025.
  • Over the past 5 years, Esperion Therapeutics' EBIT (Quarterly) stood at -$55.6 million in 2021, then increased by 23.58% to -$42.5 million in 2022, then grew by 0.34% to -$42.4 million in 2023, then skyrocketed by 89.57% to -$4.4 million in 2024, then skyrocketed by 37.86% to -$10.0 million in 2025.
  • Its EBIT stands at -$10.0 million for Q3 2025, versus $7.1 million for Q2 2025 and -$22.1 million for Q1 2025.